Regeneron Pharmaceuticals Stock Position Increased by AE Wealth Management

Institutional investor boosts stake in biotech firm by over 36% in Q4 2025

Apr. 20, 2026 at 7:06am

Got story updates? Submit your updates here. ›

An extreme close-up of complex pharmaceutical manufacturing equipment, gears, and mechanical components in shades of silver, steel, and chrome, conceptually representing the advanced science and technology behind Regeneron's drug development.Regeneron's state-of-the-art manufacturing capabilities are a key driver of investor confidence in the biotech firm's long-term growth potential.Tarrytown Today

AE Wealth Management LLC increased its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 36.7% in the fourth quarter of 2025, according to the company's latest 13F filing with the Securities and Exchange Commission. The fund now owns 5,474 shares of the biopharmaceutical company's stock valued at $4,226,000.

Why it matters

Regeneron is a leading biotech firm known for its innovative drug discovery technologies and pipeline of biologic therapies. This institutional investment signals continued confidence in the company's long-term growth prospects within the pharmaceutical industry.

The details

Other major investors have also recently adjusted their Regeneron holdings. Meyer Handelman Co. increased its stake by 0.6%, while CoreCap Advisors LLC, Whittier Trust Co., and Strait & Sound Wealth Management LLC all made smaller increases to their positions in the fourth quarter.

  • The 13F filing reporting the increased stake was submitted in the fourth quarter of 2025.
  • Regeneron's stock price opened at $750.57 on Monday, April 20, 2026.

The players

AE Wealth Management LLC

An institutional investment management firm that increased its stake in Regeneron Pharmaceuticals by 36.7% in Q4 2025.

Regeneron Pharmaceuticals, Inc.

A U.S.-based biotechnology company that focuses on discovering, developing, manufacturing, and commercializing medicines for serious medical conditions.

Got photos? Submit your photos here. ›

The takeaway

This increased institutional investment in Regeneron Pharmaceuticals reflects the company's status as a leader in innovative biopharmaceutical research and development, with a strong pipeline of potential new therapies that continue to attract the attention of major investors.